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ABSTRACT 
A poor vitamin D status, i.e. low serum levels of 25-hydroxyvitamin D (25[OH]D), is common 
in the general population. This finding is of concern not only because of the classic vitamin D 
effects on musculoskeletal outcomes, but also because expression of the vitamin D receptor 
(VDR) and vitamin D metabolizing enzymes in the heart and blood vessels suggests a role of 
vitamin D in the cardiovascular system. VDR-knockout mice suffer from cardiovascular disease 
(CVD) and various experimental studies suggest cardiovascular-protection by vitamin D, 
including anti-atherosclerotic, anti-inflammatory and direct cardio-protective actions, beneficial 
effects on classic cardiovascular risk factors as well as suppression of parathyroid hormone 
(PTH) levels. In epidemiological studies, low levels of 25(OH)D are associated with increased 
risk of CVD and mortality. Data from randomized controlled trials (RCTs) are sparse and have 
partially, but not consistently, shown some beneficial effects of vitamin D supplementation on 
cardiovascular risk factors (e.g. arterial hypertension). We have insufficient data on vitamin D 
effects on cardiovascular events, but meta-analyses of RCTs indicate that vitamin D may 
modestly reduce all-cause mortality. Despite accumulating data suggesting that a sufficient 
vitamin D status may protect against CVD, we still must wait for results of large-scale RCTs 
before raising general recommendations for vitamin D in the prevention and treatment of CVD. 
In current clinical practice the overall risks and costs of vitamin D supplementation should be 




Vitamin D is classically known for its crucial role in calcium and bone metabolism.1,2 Recent 
advances in research provoked enormous public health interest in vitamin D: (i) the vitamin D 
receptor (VDR) was identified in almost all human cells,2 (ii) vitamin D deficiency was shown to 
be highly prevalent among general populations3 and (iii) vitamin D deficiency has been 
associated with various chronic diseases including cardiovascular diseases (CVDs), which are 
the leading causes of death.1,2,4 In this review we summarise and discuss current knowledge on 
the association of vitamin D with CVD and mortality. We start with an overview of vitamin D 
metabolism, vitamin D`s history in science, and the current prevalence of vitamin D deficiency. 
Then, we summarise mechanistic and clinical data on the role of vitamin D for the 
cardiovascular system and for CVD risk factors. Finally, we present epidemiological and 
interventional data of vitamin D administration, CVD, and mortality and offer some guidance for 
treating vitamin D deficiency.  
 
BASIC VITAMIN D METABOLISM 
Sunlight induced vitamin D synthesis in the skin accounts for about 80% of obtained vitamin D.5 
Specifically, ultraviolet-B (UV-B) radiation induces the conversion of 7-dehydrocholesterol to 
previtamin D which spontaneously isomerises to vitamin D.6 This vitamin D production by 
sunlight exposure is particularly efficient in individuals with low levels of skin melanin. 
Therefore, an intriguing hypothesis suggests that in human evolution, those individuals migrating 
to northern regions developed a fair skin to efficiently synthesize vitamin D under conditions of 
less UV-B exposure, whereas those individuals residing in sunny regions have a high melanin 
content of the skin, which protects against sunlight-induced damage.7,8 Diet makes a relatively 
small contribution to vitamin D status.1,5 Vitamin D can be obtained from natural foods (e.g. oily 
  
fish, eggs, or UV irradiated and sun dried mushrooms), vitamin D-fortified food (e.g. vitamin D-
fortified milk and orange juice in the US) or vitamin D supplements.1 Two major forms of 
vitamin D exist: vitamin D3 (cholecalciferol), the main vitamin D form derived mainly from 
synthesis in the skin and from animal sources, and vitamin D2 (ergocalciferol), the plant- and 
yeast-derived form. Unless otherwise stated, we do not differentiate between these two isoforms 
in this review and usually refer to vitamin D (meaning both vitamin D2 and D3) in general. 
Vitamin D as a precursor compound exerts no significant biological activity. Two 
hydroxylation steps are required to produce the most active vitamin D metabolite, 1,25-
dihydroxyvitamin D (1,25[OH]2D).6 First, vitamin D from any source is hydroxylated to 25-
hydroxyvitamin D (25[OH]D). This is generally a substrate-dependent process that occurs 
mainly in the liver. Then, the enzyme 1α-hydroxylase converts 25(OH)D to 1,25(OH)2D. The 
kidney is the major site for production of circulating 1,25(OH)2D. Serum levels of 1,25(OH)2D 
are therefore significantly determined by renal 1α-hydroxylase activity, which is tightly 
regulated by factors related to calcium and phosphorus metabolism (e.g. stimulation by 
parathyroid hormone [PTH] or inhibition by fibroblast-growth factor 23). Correlations of serum 
level of 25(OH)D and 1,25(OH)2D are usually not very strong and patients with low 25(OH)D 
levels frequently have relatively high 1,25(OH)2D levels as a consequence of PTH-induced 
stimulation of renal 1α-hydroxylase activity. Many extra-renal tissues also express 1α-
hydroxylase, which can produce significant tissue levels of 1,25(OH)2D.6 In contrast to renal 1α-
hydroxylase activity such local production of 1,25(OH)2D seems to be significantly dependent 
on the substrate availability of 25(OH)D, but in addition is also regulated by other parameters 
such as cytokines or growth factors.6 Hence, a widely accepted hypothesis is that serum levels of 
25(OH)D are the main determinant of 1,25(OH)2D tissue levels in various organs. Further 24-
hydroxylation of 25(OH)D or 1,25(OH)2D is considered the main degradation process and 
produces vitamin D metabolites (24,25[OH]2D or 1,24,25[OH]3D) which are converted to water 
  
soluble inactive calcitroic acid. VDR activation induces this 24-hydroxylase, resulting in a 
regulatory loop.6 This process seems to be important for overall vitamin D metabolism because 
recent data suggest that the decline of circulating 1,25(OH)2D in chronic kidney disease (CKD) 
might be a consequence of increased inactivation (24-hydroxylation) rather than of reduced 
production (1α-hydroxylation) of 1,25(OH)2D.9 Plasma 1,25(OH)2D concentrations are usually 
not measured as part of the clinical routine except in rare cases (e.g. VDR dependent rickets and 
granuloma-forming diseases such as sarcoidosis).1 Low 1,25(OH)2D concentrations are 
associated with adverse health outcomes including CVD.10 Furthermore, studies on treatment 
with 1,25(OH)2D or selective VDR activators (e.g. paricalcitol) documented various beneficial 
effects on CVD as well as improved overall survival in CKD patients.11 A detailed discussion of 
this issue is, however, beyond the scope of this review. 
Vitamin D metabolites circulate in serum mainly bound to vitamin D binding protein 
(DBP). Concentrations of 25(OH)D are up to 1000-fold higher than plasma 1,25(OH)2D 
concentrations. 25(OH)D also has a significantly longer half-life than that of 1,25(OH)2D (2-3 
weeks versus 4-6 hours). DBP is important not only for transport of vitamin D metabolites in the 
bloodstream, but also for uptake of 25(OH)D or 1,25(OH)2D by target cells.6 However, our 
understanding on the cellular uptake of vitamin D metabolites in many target tissues is still in its 
infancy.6 
Vitamin D metabolites exert their effects by binding to the almost ubiquitously expressed 
cytoplasmatic VDR.2 After ligand binding this receptor forms a heterodimer with retinoid X 
receptor (RXR) and translocates to the nucleus. There, this complex interacts with specific DNA 
regions, called vitamin D-responsive elements. By additional interactions with coregulatory 




Historically, vitamin D (alphabetically named “D” as the fourth known vitamin) was 
discovered by McCollum et al. in 1922 as the substance that cured rickets, a bone disease in 
children characterized by bone pain and skeletal deformities.12 Even before McCollum identified 
vitamin D, it has already been known that sunlight was effective in preventing rickets.12 The 
chemical structures of vitamin D2 and D3 have been elucidated in the 1930s. In the late 1960s 
and early 1970s, the structures of 25(OH)D and 1,25(OH)2D were characterized, respectively.2,12 
Around the mid-20th century reports on vitamin D overdosing, in particular in children, shed 
some negative light on vitamin D and until the 1970s people believed that vitamin D may even 
cause CVD. 13 In 1981, Robert Scragg raised the hypothesis that the increased CVD incidence in 
winter may be a consequence of low UV-B irradiation, with correspondingly low vitamin D 
status in that season.14 The discovery of the VDR in the rat heart by Robert Simpson in 1983 
further stimulated research on vitamin D and CVD.15 Over the last three decades and several 
reports have described vitamin D´s effects on the cardiovascular system. 
 
PREVALENCE OF VITAMIN D DEFICIENCY 
Serum concentrations of 25(OH)D are the best parameter to assess whole-body vitamin D 
status. Therefore, such measures are used to assess vitamin D deficiency.16 However, no general 
consensus has yet emerged on 25(OH)D cut-off levels for vitamin D status and debate on how to 
classify vitamin D status is ongoing. Cut-off levels were initially based on vitamin D´s effects on 
calcium metabolism. A poor vitamin D status is associated with decreased intestinal calcium 
resorption, leading to low serum calcium levels. This condition in turn stimulates PTH secretion. 
The resulting effects of increased PTH levels on the intestines (enhanced 1,25(OH)2D 
production), bones (calcium mobilisation), and kidneys (e.g. reduced calcium loss) ensure 
adequate physiologic serum calcium levels, albeit at the expense of several deleterious effects of 
  
this secondary hyperparathyroidism. Based on this consideration the 25(OH)D level below 
which PTH levels start to rise (~75 nmol/L; to convert 25[OH]D levels from ng/mL to nmol/L 
multiply by 2.496) is frequently used for the definition of a sufficient vitamin D status (≥75 
nmol/L).1 This supposition is also in line with histomorphometric analyses of bone biopsies that 
showed pathologic mineralisation defects in patients with 25(OH)D serum levels below 75 
nmol/L.17 A proposed vitamin D status classification, which we support, differentiates between 
the following groups: vitamin D sufficiency (≥ 75 nmol/L), vitamin D insufficiency (50 to 74 
nmol/L) and vitamin D deficiency < 50 nmol/L) (see Figure 1).1 Some authors use lower 
thresholds for vitamin D deficiency, such as cut-offs of <37.5 nmol/L or < 25 nmol/L.18 The 
Institute of Medicine (IOM) in the US classified vitamin D sufficiency as 25(OH)D levels 
ranging from 50 to 125 nmol/L.19 More recently, classifications of vitamin D status have also 
been based on 25(OH)D levels at which the risk of adverse health outcomes increases 
significantly; a level of ~ 75 to 100 nmol/L (=optimal range) is associated with the best 
outcomes for multiple diseases.4,20 This optimal range, which lies exactly in the middle of the 
IOM vitamin D sufficiency range, is however based only on observational data including 
achieved 25(OH)D concentrations from meta-analyses of RCTs because no published 
interventional studies exist on, for example, CVD or mortality outcomes with specific target 
concentrations of 25(OH)D.4 Therefore, any vitamin D status classification, including the one we 
propose (see Figure 1), is debatable unless sufficient data from RCTs are available to support 
that targeting certain 25(OH)D ranges reduces hard endpoints such as CVD or mortality. 
25(OH)D levels of 250 nmol/L can be considered as safe and are used by several reference 
laboratories as the safe upper limit of normal. This safe upper limit of normal is based mainly on 
the evidence level of an expert opinion and was chosen because 25(OH)D concentrations of 250 
nmol/L can be achieved but are rarely exceeded by healthy subjects who have spent prolonged 
periods in a sunny environment.4,21 However, only limited clinical data are available on the long-
  
term prognosis of individuals with 25(OH)D levels > 125 to 150 nmol/L.4 Vitamin D toxicity 
begins at 25(OH)D levels  >375 to 500 nmol/L (see Figure 1).1,4 
Mithal et al. aimed to review the global vitamin D status.3 Reduced 25(OH)D levels (<75 
nmol/L) are highly prevalent in almost every region of the world.3 Risk factors for low 25(OH)D 
levels were advanced age, female sex, winter season, darker skin pigmentation, less sunlight 
exposure and low intake of vitamin D by diet including absence of vitamin D fortification of 
food items. In Europe or the US, the majority of the general population has 25(OH)D serum 
concentrations below 75 nmol/L. Data from the US indicating that the prevalence of low 
25(OH)D concentrations is still increasing.22,23 Specifically, 25(OH)D levels in the US 
population declined from 1988-1994 to 2000-2004, although the worsening of vitamin D status 
may be partially attributed to assay differences.22,23 Seasonal variation of vitamin D status, the 
amplitude of which increases with distance from the equator, must be considered. In the UK, the 
values at the end of summer are ~50% higher compared to the end of winter and even in South 
Florida a significant 14% increase of 25(OH)D levels was observed during summertime.5,24 
Genetics also influence circulating 25(OH)D concentrations.25 Wang et al. found three genetic 
loci that were significantly related to 25(OH)D levels.25 One gene is involved in metabolism of 
the vitamin D precursor 7-dehydrocholesterol, another one encodes an enzyme with 25-
hydroxylase activity and the third one is the DBP.25 
One should also consider different characteristics of 25(OH)D assays when determining 
vitamin D status.26 Whereas data on cut-off levels for vitamin D status are generally based on the 
DiaSorin radioimmunoassay, the increasing request for 25(OH)D measurements has prompted 
the development of various automated immunoassays.26 
 
  
VITAMIN D AND CARDIOVASCULAR RISK FACTORS 
In the following we summarise clinical and mechanistic evidence on the effect of vitamin D 
status on cardiovascular risk factors (see Figure 2). 
PTH levels are inversely correlated with 25(OH)D concentrations and epidemiological studies 
demonstrated that elevated and high-normal PTH levels are associated with an increased risk of 
cardiovascular events and mortality.27 Mechanistically, PTH increases blood pressure and exerts 
various effects on the heart including myocardial hypertrophy and pro-arrhythmic actions.28 PTH 
suppression by vitamin D supplementation might therefore reduce cardiovascular risk. 
Low 25(OH)D levels are an independent risk factor for prevalent and incident hypertension.29 
Moreover, meta-analyses of randomized controlled trials (RCTs) documented that vitamin D 
supplementation lowers systolic blood pressure by 2 to 6 mm Hg. 30-32 This latter effect was 
statistically significant in two of three meta-analyses.30-32 Proposed antihypertensive effects of 
vitamin D include PTH suppression, reno- and vasculo-protective properties, and anti-
inflammatory and anti-diabetic actions. In addition, 1,25(OH)2D has been shown to suppress 
renin transcription.2,33 Molecular pathways for this effect have already been clarified, and this 
finding is in line with observations of VDR and 1α-hydroxylase-knockout mice who display 
increased activity of the renin-angiotensin aldosterone system (RAAS).2,33 
CKD patients are particularly prone to low 25(OH)D levels.34 This outcome can be attributed to 
morbidity-related limitations in sunlight exposure, impaired vitamin D synthesis in the skin, 
malnutrition, and disturbances in vitamin D metabolism, such as loss of protein-bound vitamin D 
metabolites via the urine in proteinuric patients.34 Interestingly, a poor vitamin D status is a risk 
factor for decline in renal function.34 This may be explained by several reno-protective effects of 
vitamin D such as anti-proteinuric (e.g. vitamin D might increase megalin-mediated tubular 
protein reabsoprtion) and antihypertensive properties, suppression of the RAAS, and anti-
inflammatory and anti-autoimmunological actions.5,34 
  
A poor vitamin D status is partially, but not consistently, associated with a higher prevalence and 
incidence of type 2 diabetes mellitus.35 Vitamin D metabolites stimulate insulin secretion and 
improve insulin sensitivity, for example, by upregulating the insulin-receptor.35 Some, but not 
all, interventional studies have shown that vitamin D supplementation improves glucose 
metabolism for example, by reducing insulin resistance.35 Vitamin D may also be important for 
preventing type 1 diabetes mellitus. Low vitamin D intake during childhood and low solar UV-B 
radiation are associated with an increased risk of developing type 1 diabetes mellitus.35,36 In 
addition, variants of genes involved in vitamin D metabolism and related to 25(OH)D levels are 
associated with risk of type 1 diabetes.37 Vitamin D affects autoimmunological processes by 
increasing regulatory T cells (Tregs), which protect against autoimmunity.38 Whether vitamin D 
supplementation is definitely useful to prevent or treat type 1 and type 2 diabetes mellitus 
remains to be proven in RCTs. 
Some RCTs have already documented anti-infectious and anti-inflammatory actions of vitamin 
D such as reduction of the inflammation marker tumor necrosis factor-α (TNF-α) and increases 
of the anti-inflammatory cytokine interleukin-10 (IL-10).2,39-41 
Vitamin D may also affect other cardiovascular risk factors such as blood lipids or coagulation 
parameters but currently available data are insufficient to draw final conclusions.42,43 
 
VITAMIN D EFFECTS ON HEART AND BLOOD VESSELS 
Evidence is accumulating, that vitamin D may also exert various direct effects on the 
cardiovascular system (see Figure 3). Heart and blood vessels are target tissues for vitamin D and 
express both VDR and 1α-hydroxylase.2,44-47 In the following, we summarise experimental and 
observational clinical studies on the role of vitamin D for the heart and blood vessels. 
VDR-knockout and 1α-hydroxylase-knockout mice develop heart failure despite normalised 
calcium levels.2,45,48,49 Increased activation of the RAAS seems to be the mediating pathway 
  
because RAAS blockade with, for example, the ACE-inhibitor captopril reverses cardiac 
abnormalities in these mouse models.2,48,49 Preliminary data published in abstract form suggest 
that even cardiomyocyte-specific VDR-knockout mice develop myocardial damage.50 The 
crucial role of vitamin D for myocardial health is further supported by increased VDR 
expression in myocardial hypertrophy.45,46 VDR expression increased in cardiac myocytes and 
fibroblasts after treatment with the pro-hypertrophic vasoactive peptide endothelin.46 
Experimental studies documented anti-hypertrophic and anti-proliferative actions of vitamin D 
metabolites, which downregulate several genes involved in the development of myocardial 
hypertrophy.45,51 VDR activation modulates cardiac calcium flux and thereby induces an 
accelerated relaxation of cardiomyocytes, which may improve diastolic function of the heart.45,52 
Vitamin D-mediated regulation of cardiac extracellular matrix (ECM) turnover may also be 
important to maintain cardiac health.45,53  In this context, a study of 171 healthy British 
Bangladeshi adults, showed that matrix metalloproteinase-9 (MMP-9) is elevated in vitamin D 
deficient individuals but is significantly decreased after vitamin D supplementation.53 Several 
clinical studies confirmed that heart failure patients have a poor vitamin D status but whether 
vitamin D deficiency is only the consequence of heart failure or possibly contribute to 
myocardial diseases is unclear.45 Interventional trials produced inconsistent results on the effect 
of vitamin D on parameters of myocardial structure and function warranting further large-scale 
RCTs.40,45 
Vitamin D may also protect against atherosclerosis, vascular calcification and endothelial 
dysfunction.44 Anti-atherosclerotic vitamin D effects may include (i) inhibition of macrophage 
cholesterol uptake and foam cell formation, (ii) downregulation of vascular smooth muscle cell 
(VSMC) proliferation and migration, and (iii) suppression of inflammation triggered endothelial 
activation and expression of endothelial adhesion molecules.44,54-56 Vitamin D effects may also 
protect against endothelial dysfunction, for example, by anti-oxidative actions and by inhibiting 
  
lipid peroxidation.44,57 Finally, vitamin D may reduce vascular calcification, for example, by 
inhibiting bone morphogenic proteins, but data on this topic are somewhat controversial.44,58 
This could be attributed to the fact that both a poor vitamin D status as well as vitamin D 
intoxication may contribute to vascular calcification, although it should be noted that the largest 
study on vitamin D plus calcium supplementation found no effect on coronary artery 
calcification.54,59  
Observational and interventional studies showed inconsistent results regarding the association of 
vitamin D with vessel diseases (e.g. inconclusive data on 25[OH]D and carotid intima-media 
thickness).44,60,61 Several, but not all, interventional studies showed that vitamin D 
supplementation improves endothelial function.54,62 Hence, we need further RCTs before we can 
draw final conclusions on the effect of vitamin D on the vasculature.  
  
VITAMIN D AND CARDIOVASCULAR DISEASES 
Observational data 
Accumulating evidence suggests that CVD is associated with vitamin D deficiency. Various 
epidemiological studies have reported reduced 25(OH)D concentrations in patients with previous 
and prevalent cardiovascular or cerebrovascular diseases.44,45,63-66 Several prospective studies 
have addressed this issue, including the Intermountain Heart Collaborative (IHC) Study, which 
included >40,000 individuals from a general health care population.65 In this study, individuals 
with low serum concentrations of 25(OH)D were at significantly increased risk for future CVD, 
in particular for heart failure and cerebrovascular events.65 Consistent with this finding, 
population-based studies have partially, but not consistently, documented that poor vitamin D 
status is associated with an increased risk of cardiovascular events and cardiovascular mortality 
(see Table 1).66-80 Significant associations of low 25(OH)D levels and increased risk of fatal 
cardiovascular events, in particular, sudden cardiac death, were also observed in patients referred 
  
to coronary angiography, as well as in diabetic dialysis patients.81,82 Regarding specific 
cardiovascular events, a significant association of low 25(OH)D and fatal strokes was reported.64 
This finding may also have clinical relevance because post-stroke patients with such increased 
risk of vitamin D deficiency may be more prone to develop musculoskeletal complications.64 
Associations of vitamin D deficiency with incident CVD seem particularly strong in patients 
with CVD or at high risk of CVD and some indication exists for a nonlinear relationship with 
pronounced CVD risk increase at 25(OH)D concentrations below ~37.5 nmol/L.65-82 Meta-
analyses performed so far on this topic support the notion that low 25(OH)D concentrations are 
associated with incident CVD.63,66 In this context, Grandi et al. found that the risk of 
cardiovascular mortality was increased by 83% (hazard ratio 1.83; 95% CI: 1.19-2.80) in 
individuals with low 25(OH)D levels, that is, patients with 25(OH)D levels below a cut-off 
ranging from ~25 to 50 nmol/L.66 
However, one must interpret all these above-mentioned observational studies in the light that sun 
exposure habits, which may be an important confounder for the association of 25(OH)D and 
CVD, significantly determine vitamin D status. Furthermore, nutritional intake of vitamin D is 
usually related to other micronutrients (e.g. vitamins D and A in cod liver oil), which interferes 
with the ability to evaluate how vitamin D status affects CVD. Apart from this, vitamin D-
independent effects of sunlight exposure might partially drive the association of vitamin D status 
with CVD. Cardiovascular risk factors and CVD may also have a reciprocal effect on vitamin D 
status (e.g. vitamin D may affect myocardial function, but impaired myocardial function may 
cause vitamin D deficiency owing to morbidity-associated limitation of sunlight exposure). 
Single-nucleotide polymorphisms (SNPs) of the VDR and of key enzymes for vitamin D 
metabolism have also been associated with left ventricular hypertrophy, heart failure and 
coronary artery calcification. 83-85 Even though some questions on the functionality of these SNPs 
  
remain unresolved, these latter results may further support a possible causal relationship between 
vitamin D metabolism and CVD .83-85 
 
Data from interventional studies  
Results of RCTs designed primarily to assess effects of vitamin D supplementation on CVD are 
still missing. Data on vitamin D and CVD are derived mainly from studies designed to evaluate 
vitamin D´s effect on musculoskeletal outcomes.86 Most of those studies evaluated the impact of 
combined calcium plus vitamin D supplementation.86 This approach limits the ability to 
differentiate the effects of vitamin D from those of calcium. This factor may be important 
because calcium per se might even be harmful in terms of cardiovascular outcomes.86,87 A 
systematic review identified two RCTs with exclusive vitamin D supplementation that reported 
on CVD events as a secondary outcome.86 These studies, with vitamin D doses of approximately 
1000 IU per day, found a moderate, but statistically nonsignificant, reduction in CVD risk 
(pooled relative risk, 0.90 [95% CI, 0.77 to 1.05]) in the vitamin D group.86 Further large studies 
have been initiated to definitively prove whether vitamin D supplementation reduces CVD in the 
general population, but these studies will still take several years (e.g. the VITAL; see 
www.vitalstudy.org). 
  
VITAMIN D AND TOTAL MORTALITY 
Beyond CVD, vitamin D deficiency is associated with increased risk of total mortality. Most, but 
not all, studies on this topic documented increased mortality in patients with low 25(OH)D 
concentrations.68,70-82 A meta-analysis among 6853 CKD patients showed that mortality risk 
decreases by 14% (relative risk 0.86 [95% CI 0.82-0.91]) per 25 nmol/L increase in 25(OH)D 
levels.88 This finding is in line with the results of a meta-analysis of RCTs including mainly 
studies on frail, elderly patients.89 In this report of Autier and Gandini, vitamin D 
  
supplementation was associated with a significant 7% decrease in total mortality (summary 
relative risk 0.93 [95% CI 0.87-0.99]).89Another meta-analysis on vitamin D and its analogues 
showed less significant results and reported a significant mortality reduction only in patients with 
the combined treatment of vitamin D plus calcium (relative risk 0.94 [95% CI 0.89-0.99].90 
 
VITAMIN D TREATMENT GUIDANCE 
Vitamin D treatment can be done by either vitamin D supplementation or UV-B exposure. 
Increased vitamin D intake by natural or vitamin D-fortified food is usually not sufficient to 
correct vitamin D deficiency.1 
Vitamin D supplementation is relatively easy, cheap and safe. Supplementation can be done with 
vitamin D3, which is almost exclusively used in Europe, or with vitamin D2. Several studies 
addressed the question whether vitamin D3 is superior to vitamin D2 in raising and maintaining 
25(OH)D serum concentrations but study results are inconsistent so that it is still not clear 
whether vitamin D3 should be preferred over vitamin D2. 91,92 According to a rule of thumb, a 
daily intake of 1,000 IU of vitamin D increases 25(OH)D concentration by approximately 25 
nmol/L (15 to 25 nmol/L).91 Daily, weekly, or monthly dosing regimens can be applied because 
they produce comparable increases of 25(OH)D levels. Some authors recommend loading doses 
at the beginning of vitamin D supplementation (i.e. 50,000 IU of vitamin D weekly for 8 
weeks).1 High-dose vitamin D supplementation only once or just a few times per year, however, 
can currently not be recommended because no sufficient long-term outcome data exist on doses 
of >100,000 IU. Such unphysiologic high doses may even be harmful.93 Therefore, we should be 
cautious with high dose vitamin D supplementation also when considering that some study 
results suggest a J-shaped association of 25(OH)D and mortality.70 Individual variations in 
response to vitamin D supplementation should be considered, and in particular, obese individuals 
require higher doses as a result of vitamin D depletion in the adipose tissue.4 In patients with 
  
vitamin D insufficiency or deficiency it has been shown that the lower the baseline 25(OH)D 
levels, the greater is the increase of 25(OH)D after vitamin D supplementation.94 Re-testing of 
25(OH)D concentrations may therefore be reasonable, also in an effort to improve compliance, 
but this should be done only 3 months after initiation of vitamin D supplementation which is the 
time necessary to reach a plateau.4 No adverse effects have been observed with daily vitamin D 
intakes of up to 10,000 IU.95 Potential side effects of vitamin D (i.e. vitamin D intoxication) are 
seen at 25(OH)D serum levels > 375 nmol/L to 500 nmol/L and are related to symptoms of 
hypercalcemia with the risk of calcifications (e.g. of the vessels or the kidney) and hypercalciuria 
with dehydration and renal failure.95 No convincing evidence exists that vitamin D 
supplementation alone increases the risk of kidney stones, but the combined supplementation of 
calcium plus vitamin D may be associated with significantly increased incidence of kidney 
stones.95   
Increased sunlight exposure of the skin can also significantly increase 25(OH)D serum 
concentrations. Sunlight induced vitamin D synthesis in the skin can be equivalent to a daily 
vitamin D supplementation of up to 10,000 to 20,000 IU.1 However, the skin´s capacity to 
produce vitamin D decreases with age, sunscreen use and increasing skin pigmentation. Hence, 
significant interindividual differences in cutaneous vitamin D synthesis exist, but it seems that ~ 
15 to 30 minutes of sunlight exposure of the skin (legs and arms) between 10 am and 3 pm for at 
least three times per week is usually enough for a sufficient vitamin D synthesis.1,12,96 
Interestingly, excessive sunbathing is not associated with very high 25(OH)D concentrations 
because excess previtamin D3 and vitamin D3 are photodegraded.12 This finding explains why 
there are no known cases of sunlight induced vitamin D intoxication. It should also be 
considered that at northern and southern latitudes above and below ~33° sunlight exposure 
during wintertime is not sufficient for vitamin D synthesis in the skin. However, excessive 
sunlight exposure increases the risk of non-melanoma skin cancer. By contrast, accumulating 
  
evidence suggests that vitamin D may be beneficial for various other types of cancers.1,2,96 
Dermatologists have therefore started to change their “no sun policy” towards recommendations 
for moderate sun exposure, which may even protect against melanomas.96 
 
VITAMIN D TREATMENT RECOMMENDATIONS 
None of the major Cardiology Societies has recently proposed specific recommendations 
regarding vitamin D. We therefore briefly discuss recommendations from various other societies 
or expert panels that may be interesting for those who consider vitamin D supplementation in 
patients with CVD or at high risk of CVD. 
Based on positive vitamin D effects on “bone health” the 2011 report from the IOM recommends 
a 25(OH)D level of at least 50 nmol/L.19 The report asserts that the daily vitamin D intake should 
be 600 IU for individuals up to the age of 70 years and 800 IU for older adults of the general 
population corresponding to the Recommended Daily Allowance (RDA, covering requirements 
of ≥ 97.5% of the population).19 These RDAs of the IOM report are based on an assumption of 
minimal or no sun exposure. Given that in general populations the average daily vitamin D 
intake by diet (nutrition) is usually not higher than ~200 IU, this would mean that vitamin D 
supplementation may be indicated in most individuals of the general population. Tolerable Upper 
Intake Levels (UL) were set at 4,000 IU per day in the 2011 IOM statement.19 Moreover, the 
2009 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines include 
a recommendation to test for and treat vitamin D deficiency and insufficiency (25[OH]D levels) 
in CKD patients stages 3-5D (glomerular filtration rate [GFR] below 60 ml/min/1.73m²).97 This 
recommendation is based on a low evidence level but impaired vitamin D metabolism may have 
deleterious consequences on renal function, proteinuria, and outcome in CKD patients. 34,82,85,98 
Further expert panels have recommended supplementing 800 IU of vitamin D in all individuals 
older than 65 years, and one expert panel recommended testing for and treating vitamin D 
  
deficiency in all patients with or at high risk of CVD.4,99 We also draw attention to the fact that 
vitamin D supplementation is generally recommended in the first year of life (usually 400 IU per 




Vitamin D deficiency is common and the cardiovascular system is a target tissue for vitamin D. 
Experimental studies showed beneficial vitamin D effects on cardiovascular risk factors, the 
heart, and the blood vessels. Clinical studies have largely, but not consistently, indicated that 
CVD and mortality are associated with vitamin D deficiency. Data from RCTs, however, are 
sparse, and some, but not all, studies showed beneficial effects of vitamin D supplementation on 
cardiovascular risk factors (e.g. arterial hypertension). Available data are insufficient to draw 
final conclusions on the effect of vitamin D supplementation on CVD events, but results from 
meta-analyses suggest that vitamin D treatment may modestly reduce all-cause mortality. The 
above-mentioned promising data on cardiovascular-protective properties of vitamin D have 
stimulated the initiation of large-scale RCTs to evaluate the effect of vitamin D on 
cardiovascular outcomes. These studies will, however, not be finished within the next few years, 
leaving us with the question of how to handle vitamin D testing and treating in the clinical 
routine. On the basis of current evidence, we cannot justify proposing general recommendations 
for vitamin D supplementation for the treatment and prevention of CVD. However, we also 
cannot ignore the available knowledge on vitamin D. Consequently, we are of the opinion that 
overall risks and cost of vitamin D supplementation should be weighed against potential adverse 
consequences of untreated vitamin D deficiency. In this context, the proposed multiple health 
benefits of vitamin D and the relatively easy, cheap, and safe manner of its supplementation 
should be considered. 1,2,4,89,95,99 Currently available data suggest that  25[OH]D levels of ~75 to 
  
100 nmol/L are associated with the best health outcomes and we therefore believe that aiming for 
this “optimal range” of vitamin D status is reasonable. However, we should be aware that these 
data on the optimal vitamin D status are based on relatively low evidence levels, are 
controversially discussed, and need to be further evaluated in large-scale RCTs. 
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risk (95% CI) 
Wang67 USA 59 45 1,739 5.4 CV events 120 <37.5 vs. ≥37.5 1.66 (1.13-2.43) 
Giovannucci69 USA 64 100 1,345 10 Myocardial infarction 454 
≤37.5 vs. 
≥37.5 2.09 (1.24-3.54) 
Melamed70* USA 45 47 13,331 8.7 CV 
mortality 777 
<44.4 vs 
>80.1 1.20 (0.87-1.64) 
Semba76 Italy 74 75 1,006 6.5 CV 
mortality 107 
<26.2 vs. 
>63.9 2.64 (1.68-2.19) 






Kilkkinen71 Finland 49 45 6,219 27.1 CV 
mortality 933 ≥62 vs. ≤28 0.76 (0.61-0.95) 
Bolland74 New Zealand 74 0 1,471 4 CV events 110 <50 vs ≥50 1.2 (0.8-1.8) 









first vs. fourth 
quartile 
1.08 (0.79-1.48)     
0.93 (0.61-1.44) 
Fiscella78* USA 44 48 15,363 9 CV 
mortality 933 
>79.9 vs. 
<44.9 0.79 (0.62-1.01) 
Cawthon72 USA 74 100 1,490 7.3 CV 
mortality 110 <50 vs ≥75 1.51 (0.83-2.80) 
Jassal75 USA 74 38 1,073 6.4 CV 
mortality 111 per SD=35 1.07 (0.86-1.33) 
Michaëlsson73‡ Sweden 71 100 1,194 12.7 CV 
mortality 177 <46 vs. 46-93 1.53 (0.97-2.41) 
Virtanen79 Finland 62 49 1,136 9.1 CV 
mortality 35 
≤34.0 vs. 
≥34.1 2.70 (1.31-5.56) 
Messenger80‡ USA 76 100 813 4.4 CV events 140 ≤50.2 vs. ≥75.1 1.18 (0.69-2.03) 
*Both reports on the same study: Third National Health and Nutrition Examination Survey (NHANES-III) 
†Separate reports for non-smokers (upper line) and smokers (lower line) 












Figure 1: Proposed vitamin D status classification 
 
Figure 2: Associations of vitamin D deficiency with cardiovascular risk factors 
 
Figure 3: Proposed vitamin D effects on heart and blood vessels 
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